Fulgent Genetics Inc. is a publicly traded health care technology company that specializes in genetic testing services, with a market capitalization of approximately $560.47 million.

Fulgent Genetics, a genetic testing company, navigates stock market fluctuations and valuation challenges, but remains well-positioned to capitalize on the growing demand for personalized medicine.

Fulgent Genetics continues to navigate market volatility with a steady focus on genetic testing services, maintaining a robust market capitalization and commitment to advancing patient care and outcomes.

Fulgent Genetics reports its quarterly earnings estimate, with a moderate stock price of $18.88 USD, despite facing challenges in profitability and volatility in the biotech sector.

Fulgent Genetics Inc. has disclosed its quarterly earnings estimate, with its stock price experiencing significant fluctuations over the past year.